Cell & BioscienceDevelopmental BiologyPeer-reviewed journal article
Modelling Porcine NAFLD by Deletion of Leptin and defining the role of AMPK in hepatic fibrosis
Tan Tan, Zhiyuan SongiD, Wenya LiiD, Runming WangiD, Mingli ZhuiD, Zuoxiang LiangiD, Yilina Bai, Qi WangiD, Hanyu WuiD, Xiaoxiang HuiD, Yiming XingiD
Abstract
Liver fibrosis occurs during chronic liver disease. Advanced liver fibrosis results in cirrhosis, liver failure and often requires liver transplantation. However, due to the lack of human models, mechanisms underlining the pathogenesis of liver fibrosis remain unclear. Recent studies implicated a central role of deranged lipid metabolism in its pathogenesis. In this study, we generated LEPTIN-deficient (LEPTIN-/-) pigs using zinc finger nuclease technology to investigate the mechanisms of liver fibrosis associated with obesity. The LEPTIN-/- pigs showed increased body fat and significant insulin resistance by 12 months of age. To resemble non-alcoholic fatty liver disease (NAFLD) patients, LEPTIN-/- pig developed the phenotypic features of fatty liver, non-alcoholic steatohepatitis (NASH) and hepatic fibrosis with age. Meanwhile, LEPTIN absence reduced phosphorylation of JAK2-STAT3 and AMPK. The alteration of JAK2-STAT3 enhanced fatty acid {beta}-oxidation, whereas inactivation of AMPK led to mitochondrial autophagy, and both contributed to increased oxidative stress in hepatocytes. Although Leptin deletion in the rat liver altered JAK2-STAT3 phosphorylation, it activated the AMPK pathway and prevented liver fibrogenesis in contrast with the LEPTIN-/- pig. To our knowledge, the LEPTIN-/- pig provides the first model recapitulating the full pathogenesis of NAFLD and its progression toward liver fibrosis. The activity of AMPK signaling pathway suggests a potential target for development of new strategies for the diagnosis and treatment of NAFLD.
- Citations
- 14
- FWCI
- 2.59
- Field percentile
- top 9%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Direct β1/β2 AMPK activation reduces liver steatosis but not fibrosis in a mouse model of non-alcoholic steatohepatitis
KARLY M. MATHER, Michelle L. Boland, … David M. Smith·bioRxiv·May 30, 2024
- FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis
C. Liu, M. Schönke, … P. C. Rensen·bioRxiv·Sep 20, 2022
- MKP1 promotes nonalcoholic steatohepatitis by suppressing AMPK activity through LKB1 nuclear retention
B. Qiu, A. Lawan, … A. M. Bennett·bioRxiv·Jul 10, 2023
- Deficiency of gluconeogenic enzyme PCK1 promotes non-alcoholic steatohepatitis progression and fibrosis through PI3K/AKT/PDGF axis activation
- Oral supplementation of gut microbial metabolite indole-3-acetate alleviates diet-induced steatosis and inflammation in mice
Y. Ding, K. Yanagi, … A. Jayaraman·bioRxiv·Mar 21, 2023
- Hepatocyte-specific loss of LAP2α protects against diet-induced hepatic steatosis and steatohepatitis in male mice
K. K. Upadhyay, E.-Y. K. Choi, … G. F. Brady·bioRxiv·Mar 18, 2022